Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 5/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3254324 | 1.00 | SLC2A1 (0.49) | SLC2A1KCNH2JAK2JAK1KDM4D | |
| SCHEMBL3250355 | 1.00 | SLC2A1 (0.49) | SLC2A1KCNH2JAK2JAK1KDM4D | |
| SCHEMBL3254329 | 1.00 | SLC2A1 (0.49) | SLC2A1KCNH2JAK2JAK1KDM4D | |
| SCHEMBL6687899 | 1.00 | SLC2A1 (0.49) | SLC2A1KCNH2JAK2JAK1KDM4D | |
| SCHEMBL5726714 | 0.86 | SLC2A1 (0.61) | SLC2A1KCNH2 | |
| SCHEMBL5264092 | 0.83 | SLC2A1 (0.48) | SLC2A1KCNH2JAK2JAK1MAP4K4 | |
| SCHEMBL3249089 | 0.82 | SLC2A1 (0.46) | SLC2A1KCNH2 | |
| SCHEMBL3247718 | 0.82 | SLC2A1 (0.46) | SLC2A1KCNH2 | |
| SCHEMBL3250001 | 0.82 | SLC2A1 (0.46) | SLC2A1KCNH2 | |
| SCHEMBL3246385 | 0.82 | SLC2A1 (0.46) | SLC2A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2181996-A1 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2010-05-05 | — | — | EP | disclosed |
| US-7312212-B2 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2007-12-25 | — | — | US | disclosed |
| US-20050159411-A1 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159411-A1 | Aminopiperidine derivatives | AMPD2, AMPD3, NPEPPS | SLC2A1 3708/4885KCNH2 1182/4885JAK2 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.